News Disclaimer (Press Releases have not been investigated by Sizzling Stock Picks, therefore, we have no idea if the content of this news is based on Fact or Fiction. Although the link for the following press release may be from a familiar and reputable news source, you should NOT assume that a press wire hosted by a website you are familiar with is accurate just because it is on their site. Sizzling Stock Picks will not be held responsible for any news release, including and not limited to misleading or non-factual content, or the accuracy of the identity of the given source of the press release.)
BioSig Technologies Closes Private Placement
LOS ANGELES, CA--(Marketwired - Apr 1, 2015) - BioSig Technologies (OTCQB: BSGM), a medical device company developing PURE EP™, a proprietary technology platform designed to improve the clinical outcomes of electrophysiology (EP) procedures, today announced the Company closed a private placement of $4.009 million. Laidlaw & Co (UK) Ltd. served as the sole placement agent.
The Company issued approximately 1.6 million shares at a price of $2.50 per share: one warrant at $3.75, and a flash warrant at $2.50 exercise price expiring on July 30, 2015.
Greg Cash, BioSig CEO, said, "We are very pleased to have closed this private placement. Proceeds will be used to support our growth initiatives at BioSig Technologies."
Kenneth L. Londoner, Co-founder and Executive Chairman added, "The proceeds provided by this private placement will permit our team to move forward with our near and longer term clinical, regulatory and commercialization plans."
News 
Market Data 
Discover 
